Multi drugs resistance to Diabetes Mellitus patients with tuberculosis in Manado City

Main Article Content

Elne Vieke Rambi Dyan R Sukandar Linda Augustien Makalew Yohanis Tomastola Ketrina Konoralma


Diabetes mellitus (DM) with pulmonary tuberculosis (TB) is an infectious disease if not educated regularly, there will be a high risk of drug resistance and even some anti-tuberculosis drugs. This study aims to identify anti-tuberculosis drug resistance in DM patients with TB in Manado City. The population in the study types 2 DM patients as amount 80 patients. Based on TCM/GenExpert examination from 47 respondents, there were 17 respondents positive multi drugs resistance rifampicin (RR). Sampling taking based on inclusion criteria, i.e., have had type DM for five years, had suffered TB MDR RR based on GenXpert examination as much as 17 respondents followed in the resistance test with Sputum TB culture and MGIT method. The result of the study showed that MDR DM-TB with MGIT method as followed is obtained from 17 samples, six samples (35.30%) resistance INH 0.4 mg and 1 sample (5.88%) MDR canamycin, and still sensitive INH 0.4 mg and camaycin is ten samples (58.82%). This study results could be used to program planning of prevention and controlling efforts TB-DM in this treatment obedience and regimen anti-tuberculosis medicine for MDR-TB patients.


Download data is not yet available.

Article Details

How to Cite
Rambi, E., Sukandar, D., Makalew, L., Tomastola, Y., & Konoralma, K. (2021). Multi drugs resistance to Diabetes Mellitus patients with tuberculosis in Manado City. Jurnal Teknologi Laboratorium, 10(1), 40-45.


1. Ulfahimayati U, Medison I, Mizarti D. Diabetes Mellitus Tipe 2 sebagai Faktor Predisposisi dan Komorbid Tuberkulosis Multi Drug Resisten Primer. J Kedokt Yars. 2020;28(2):041-050. doi:10.33476/jky.v28i2.1422.
2. Song W, Shao Y, Liu J, et al. Primary drug resistance among tuberculosis patients with diabetes mellitus: a retrospective study among 7223 cases in China. Infect Drug Resist. 2019;Volume 12:2397-2407. doi:10.2147/IDR.S217044.
3. Zaragoza B, Laniado-Laborín R. Diagnosing Drug-Resistant Tuberculosis with the Xpert®MTB/RIF. The Risk for Rifampin Susceptible Cases. J Tuberc Res. 2017;05(03):155-160. doi:10.4236/jtr.2017.53017.
4. Aung MN, Moolphate, Aung M, et al. Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB. Infect Drug Resist. 2012;5(1):79. doi:10.2147/IDR.S24295
5. Siahaan AGH, Polii EBI, Ongkowijaya J. Profil pasien tuberkulosis dengan multi drug resistance (MDR). J e-Clinic. 2016;4.
6. Novianti N, Simarmata OS, Lolong DB. Pemanfaatan Tes Cepat Molekuler (TCM) Genexpert Sebagai Alat Diagnostik TB Paru di RSUD Wangaya Kota Denpasar. J Ekol Kesehat. 2020;18(3):135-148. doi:10.22435/jek.v3i18.2399.
7. Aderita NI, Murti B, Suryani N. Risk Factors Affecting Multi-Drug Resistant Tuberculosis in Surakarta and Wonogiri, Central Java, Indonesia. J Epidemiol PublicHealth. 2016;01(02):86-99. doi:10.26911/jepublichealth.2016.01.02.02.
8. Rumende CM. Risk Factors for Multidrug-resistant Tuberculosis. Acta Med Indones. 2018;50(1):1-2.
9. Mulu W, Mekkonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci. 2015;15(2):368. doi:10.4314/ahs.v15i2.9.
10. Gomes M, Correia A, Mendonça D, Duarte R. Risk Factors for Drug-Resistant Tuberculosis. J Tuberc Res. 2014;02(03):111-118. doi:10.4236/jtr.2014.23014.
11. Rodal C. Tuberculosis, Enfermedad Infecciosa Más Letal En El Mundo. Boletín UNAM-DGCS-187bis Ciudad Univ. 2018;44(2):145-152.
12. Wijaya I. Tuberkulosis Paru pada Penderita Diabetes Melitus. Cermin Dunia Kedokt. 2015;42(6):412-417.
13. Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. Marotta C, ed. PLoS One. 2021;16(2):e0246284. doi:10.1371/journal.pone.0246284.
14. Widyaningsih P, Nugroho AA, Saputro DRS, Sutanto. Tuberculosis transmission with relapse in Indonesia: susceptible vaccinated infected recovered model. J Phys Conf Ser. 2019;1217(1):012071. doi:10.1088/1742-6596/1217/1/012071.
15. Suen S, Bendavid E, Goldhaber-Fiebert JD. Disease Control Implications of India’s Changing Multi-Drug Resistant Tuberculosis Epidemic. Dowdy DW, ed. PLoS One. 2014;9(3):e89822. doi:10.1371/journal.pone.0089822.
16. Wai PP, Shewade HD, Kyaw NTT, et al. Community-based MDR-TB care project improves treatment initiation in patients diagnosed with MDR-TB in Myanmar. Shankar EM, ed. PLoS One. 2018;13(3):e0194087. doi:10.1371/journal.pone.0194087.
17. Hossain ST, Isaakidis P, Sagili KD, et al. The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh. Subbian S, ed. PLoS One. 2015;10(6):e0129155. doi:10.1371/journal.pone.0129155.
18. Li B-Y, Shi W-P, Zhou C-M, et al. Rising challenge of multidrug-resistant tuberculosis in China: a predictive study using Markov modeling. Infect Dis Poverty. 2020;9(1):65. doi:10.1186/s40249-020-00682-7.
19. Kendall EA, Azman AS, Cobelens FG, Dowdy DW. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. Chatterji D, ed. PLoS One. 2017;12(3):e0172748. doi:10.1371/journal.pone.0172748.

Most read articles by the same author(s)